Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 4/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434315 | 0.81 | CHRNA7 (0.56) | RETHTR2ACHRNA7CHRNB2CHRNA4 | |
| SCHEMBL8212470 | 0.77 | CHRNA7 (0.49) | RETHTR2ACHRNA7CHRNB2CHRNA4 | |
| SCHEMBL447419 | 0.74 | IDO1 (0.66) | RETHTR2AIDO1PDPK1 | |
| SCHEMBL7871424 | 0.73 | HTR2A (0.52) | RETHTR2AIDO1ACP3PDPK1 | |
| SCHEMBL25174905 | 0.73 | HTR2A (0.47) | RETHTR2ACHRNA7CHRNB2CHRNA4 | |
| SCHEMBL30096726 | 0.73 | HTR2A (0.47) | RETHTR2ACHRNA7CHRNB2CHRNA4 | |
| SCHEMBL13412792 | 0.72 | CYP3A4 (0.53) | RETHTR2ACHRNA7CHRNB2CHRNA4 | |
| SCHEMBL13447594 | 0.72 | HTR2A (0.47) | RETHTR2ACHRNA7CHRNB2CHRNA4 | |
| SCHEMBL19997052 | 0.72 | HTR2A (0.56) | RETHTR2AIDO1ACP3PDPK1 | |
| SCHEMBL6003168 | 0.71 | IDO1 (0.68) | CYP2D6IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371459-A1 | INDUSTRIAL PROCESS FOR PREPARATION OF 1,2-DIHYDROQUINOLINE DERIVATIVE OR A SALT THEREOF, AND INTERMEDIATE FOR PREPARATION THEREOF | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-2805948-A1 | INDUSTRIAL PROCESS FOR PREPARATION OF 1,2-DIHYDROQUINOLINE DERIVATIVE OR A SALT THEREOF, AND INTERMEDIATE FOR PREPARATION THEREOF | Santen Pharmaceutical Co., Ltd (JP) | 2014-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371459-A1 | INDUSTRIAL PROCESS FOR PREPARATION OF 1,2-DIHYDROQUINOLINE DERIVATIVE OR A SALT THEREOF, AND INTERMEDIATE FOR PREPARATION THEREOF | NR3C2, NR5A1, NR3C1 | RET 1677/4885HTR2A 2797/4885CHRNA7 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.